Phase I study to evaluate the toxicity and feasibility of intra-tumoral injection of alpha-gal glycosphingolipids [glycosphingolipids] in patients with advanced or refractory solid tumors.
Phase of Trial: Phase I
Latest Information Update: 14 May 2013
At a glance
- Drugs AGI 134 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 23 Nov 2012 Primary endpoint amended as reported by ClinicalTrials.gov.
- 21 Dec 2011 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
- 21 Dec 2011 Actual patient number is 11 according to ClinicalTrials.gov.